Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 545 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06871176Recruiting
New PET/MR scan vs standard imaging for multiple myeloma
This trial compares a new type of PET/MR scan (using a radioactive tracer called Ga-68 PentixaFor) with standard imaging to see if it can better detect multiple myeloma at diagnosis and during follow-up. It may help improve staging and treatment planning.
Toronto, OntarioAges 18 years+ - NCT06999031RecruitingEarly Phase 1
CG-105-12 for relapsed/refractory multiple myeloma
This trial tests a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma that has come back or stopped responding to other treatments. It aims to see if this therapy can help when at least 3 prior treatments have failed.
Nanchang, JiangxiAges 18–75 - NCT07044427Recruiting
Fall prevention exercise for multiple myeloma patients
This trial tests if a home exercise program can help prevent falls in people with multiple myeloma. It is for patients who are currently receiving or have recently received cancer therapy and want to exercise at least three times a week.
Heidelberg, Baden WürtembergAges 18 years+ - NCT07051850Recruiting
Quality of life study for relapsed myeloma immunotherapy
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Seocho, SeoulAges 19 years+ - NCT07069751Recruiting
Plant-based diet study for smoldering myeloma
This study tests whether a high-fiber plant-based diet can improve gut health in people with smoldering multiple myeloma. It aims to see if diet changes can slow or prevent the disease from progressing.
Milan, MilanoAges 18–75 - NCT07100067Recruiting
LCAR-F33S for Relapsed/Refractory Multiple Myeloma
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
BeijingAges 18 years+ - NCT07111884Recruiting
Multiple myeloma registry study
This study collects information from multiple myeloma patients who previously took part in a GMMG therapy study. It helps researchers learn more about the disease and treatments over time.
BerlinAges 18 years+ - NCT07139509RecruitingPhase 1
Dual-targeting CAR-T cell therapy for relapsed multiple myeloma
This trial tests a new type of immune cell therapy using donated umbilical cord blood cells that are modified to target two proteins (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has come back or is not responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, or an anti-CD38 antibody.
Xi’an, ShanxiAges 18–75 - NCT07169500RecruitingPhase 1/Phase 2
CAR-T with or without stem cell transplant for young women with myeloma
This trial tests a new immune cell therapy (BCMA-CART) alone or combined with a stem cell transplant for women aged 18-55 with multiple myeloma. It aims to see if this treatment is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–50 - NCT07214324Recruiting
Predicting blood cancer progression with genetic analysis
This study uses advanced genetic testing to see if they can predict how monoclonal gammopathies (early blood conditions that may turn into cancer) will change over time. It may help doctors understand your risk better.
BolognaAges 18 years+ - NCT07225738Recruiting
Multiple Myeloma treatment and cannabis use study
This study follows people with newly diagnosed multiple myeloma to see how their cancer treatments and use of medications, including cannabis, affect their health. It will help doctors learn more about what works best.
Goodyear, ArizonaAges 18 years+ - NCT07333430RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory multiple myeloma
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
JerusalemAges 18 years+ - NCT02869555Recruiting
Study of people with multiple myeloma in a patient database
This is a study that collects information from people diagnosed with multiple myeloma. It may help researchers understand the disease and improve future care by using past and ongoing patient data.
Marseille, Bouches-du RhôneAges 18–95 - NCT07493135RecruitingEarly Phase 1
IMV102 for relapsed/refractory multiple myeloma
This early-phase trial tests an experimental drug called IMV102 for people with multiple myeloma that has come back or stopped responding to at least 3 prior treatments. The study aims to see if IMV102 is safe and how well it works.
BeijingAges 18–80 - NCT07559799Recruiting
Melflufen and Dexamethasone for Relapsed Multiple Myeloma
This study tracks how melflufen (a cancer-fighting drug) combined with dexamethasone works in patients with multiple myeloma that has returned or stopped responding to previous treatments. Researchers will monitor your health and quality of life over time to understand the treatment's real-world effectiveness.
Freiburg im BreisgauAges 18 years+ - NCT07663253Recruiting
Isatuximab with VRd for newly diagnosed multiple myeloma patients not eligible for transplant
This trial tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone—for people with newly diagnosed multiple myeloma who cannot have a stem cell transplant. The goal is to see if adding isatuximab helps control the cancer better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07210047Enrolling by invitationPhase 1/Phase 2
Study of HuL001 for multiple myeloma that has come back or not responded
This trial tests a new drug called HuL001 combined with lenalidomide and dexamethasone for people with multiple myeloma that has returned or stopped responding to at least three prior treatments. It aims to see if this combination can help when other options have failed.
TaipeiAges 18 years+ - NCT07455851RecruitingPhase 1/Phase 2
Studying a new drug combo for relapsed or refractory multiple myeloma
This trial tests whether REGN17372 plus linvoseltamab is safe for people with multiple myeloma that has come back or not responded to prior treatments. You may join if you have tried at least 3 other therapies.
Randwick, New South WalesAges 18 years+ - NCT03110822RecruitingPhase 1
Ruxolitinib, steroids, and lenalidomide for hard-to-treat myeloma
This Phase 1 trial tests a combination of ruxolitinib plus steroids and lenalidomide in people with relapsed or refractory multiple myeloma. It’s designed for patients who have had at least two prior treatment options and whose myeloma is getting worse or not responding.
Alhambra, CaliforniaAges 18 years+ - NCT04533217Recruiting
Vertebroplasty for multiple myeloma back pain
This trial tests whether adding a procedure called vertebroplasty to usual care can better reduce back pain from multiple myeloma. It’s for people who have a small number of spine fractures in a specific area and significant pain.
Middelfart, Region SyddanmarkAges 18 years+ - NCT04603872RecruitingEarly Phase 1
CAR-T plus dasatinib for hard-to-treat B-cell cancers
This early study tests a cancer-fighting treatment that uses CAR-T cells together with dasatinib for people whose B-cell cancers have come back or did not respond. It aims to improve control of the cancer in cases that are often resistant to standard treatment.
Hangzhou, ZhejiangAges 18–70 - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT06140524RecruitingPhase 2
Study of Linvoseltamab for high-risk MGUS or smoldering myeloma
This trial tests if linvoseltamab can remove abnormal plasma cells that might turn into multiple myeloma. It is for patients with high-risk MGUS (a precancerous condition) or non-high-risk smoldering myeloma who have not yet developed active myeloma.
Baltimore, MarylandAges 18 years+ - NCT06196255RecruitingPhase 1/Phase 2
CAR-T cell therapy for resistant or relapsed multiple myeloma
This trial tests a new CAR-T cell therapy that targets FcRL5 on myeloma cells. It's for people whose myeloma has come back or stopped responding to other treatments, including stem cell transplant.
Xuzhou, JiangsuAges 18–70
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 545 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.